ARTICLE | Product Development
A Vir’s-eye view of the path forward for its COVID mAbs
Vir thinks its mAbs could be less dogged by variants and more effective in hospitalized patients than earlier entrants
March 27, 2021 2:12 AM UTC
As Vir gears up to be third to market with a COVID-19 mAb therapy, the company thinks its pipeline could see broader use than authorized products, and believes the class will become a mainstay even as variants arise, vaccines become ubiquitous and the virus goes endemic.
“We’ve had the flu vaccine for decades, but that doesn’t obviate the need for therapies,” Vir Biotechnology Inc. (NASDAQ:VIR) CMO Philip Pang told BioCentury. “We think antibody therapies will take the fear out of COVID, and unclog our hospital system.”...
BCIQ Company Profiles